Joel E

START Center to Open Lisbon, Portugal Location

First oncology early phase clinical trials unit in Portugal to offer leading-edge cancer treatments SAN ANTONIO, Aug. 16, 2022 – The START Center for Cancer Care, a San Antonio-based oncology early-phase clinical research site network, will open Portugal’s first facility in Lisbon in late 2022. START Center’s agreement with Hospital de Santa Maria – Centro […]

START Center to Open Lisbon, Portugal Location Read More »

START Center to Open Lisbon, Portugal Location

First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

Predictive and therapeutic implications of a novel PLCy1/SHP2-driven mechanism of cetuximab resistance in metastatic colorectal cancer

Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumors (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study

Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial

T cell engagers in solid tumors kick the door down

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody-Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Association of Concomitant Bone Resorption Inhibitors With Overall Survival Among Patients With Metastatic Castration-Resistant Prostate Cancer and Bone Metastases Receiving Abiraterone Acetate With Prednisone as First-Line Therapy

Combination Immunotherapy With IDO Inhibitors: Defining a Future Through Biomarker-Guided Patient Selection

Partnership

Quis volutpat scelerisque quis massa in dolor nunc lectus cursus.